Thalidomide-O-PEG2-Acid

Background Introduction

Thalidomide-O-PEG2-Acid is a specially designed E3 ligase ligand-linker conjugate widely used in targeted protein degradation research, particularly as a building block in PROTAC (Proteolysis Targeting Chimera) technology. Thalidomide serves as a high-affinity ligand for Cereblon (CRBN), a component of the CUL4-RBX1-DDB1-CRBN E3 ubiquitin ligase complex. The PEG2 linker provides enhanced solubility and optimal spacing for conjugating with various protein-targeting warheads, facilitating the formation of effective bifunctional degraders.

Mechanism

The mechanism of Thalidomide-O-PEG2-Acid centers on its role as the E3 ligase-binding moiety within PROTACs. The thalidomide portion specifically binds to CRBN, recruiting the E3 ubiquitin ligase complex. The attached PEG2 (polyethylene glycol) linker imparts flexibility and aqueous solubility, while the terminal carboxylic acid enables coupling to protein-targeting ligands (warheads) through amide or ester bond formation. When integrated into a PROTAC molecule, this conjugate mediates proximity-induced ubiquitination of the target protein, marking it for subsequent proteasomal degradation.

Applications

Thalidomide-O-PEG2-Acid is an essential intermediate for the synthesis of CRBN-recruiting PROTACs, molecular glues, and related protein degradation tools. It is valuable for drug discovery, chemical biology research, and mechanistic studies on targeted protein degradation. Researchers leverage Thalidomide-O-PEG2-Acid to develop customized PROTACs aimed at degrading disease-relevant proteins in oncology, immunology, and neurodegenerative research, thereby accelerating the advancement of next-generation therapeutics. Its structure, featuring a carboxylic acid functional group, allows for easy conjugation with various ligands and expands the toolbox for developing innovative bifunctional molecules.

• PEG2 linker increases aqueous solubility and flexibility for improved PROTAC design.
• Carboxylic acid functional group enables efficient coupling to a variety of E3 ligase ligands or target-binding ligands.

The E3 Ligase Ligand-Linker Conjugate, Thalidomide-O-PEG2-Acid, plays a crucial role in the development of PROTACs for targeted protein degradation, offering enhanced specificity and versatility. This molecule's design facilitates the strategic coupling of E3 ligase with target protein ligands to promote selective protein degradation, as detailed in the following descriptions of its linker, ligand, and target protein ligand selection.

Linker: The linker in Thalidomide-O-PEG2-Acid is a PEG2 chain, providing moderate length and flexibility, which enhances solubility and bioavailability. Its non-cleavable nature ensures stability in biological environments, making it well-suited for sustained interactions between the ligand and the target protein.

Ligand: The ligand component is derived from thalidomide, a well-characterized E3 ligase recruiter. Its structural features include a phthalimide moiety, which effectively binds to the cereblon (CRBN) E3 ligase, facilitating the ubiquitination and subsequent degradation of target proteins.

Reactive Site: The reactive site in this molecule is the carboxylic acid group, which can be activated for coupling with target protein ligands. Recommended reaction types include amide bond formation or esterification, providing robust and stable linkages for efficient PROTAC assembly.

Recommended Target Protein Ligand: A compatible warhead for Thalidomide-O-PEG2-Acid is an amine-containing moiety, which allows for efficient coupling via amide bond formation. This type of warhead is advantageous due to its stability and ability to form strong covalent bonds, making it suitable for applications requiring durable and effective target protein engagement in degradation pathways.